R R Kempker
Overview
Explore the profile of R R Kempker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smirnova N, Bryan C, Salindri A, Avaliani T, Goginashvili L, Gujabidze M, et al.
Int J Tuberc Lung Dis
. 2024 Sep;
28(10):505-507.
PMID: 39334541
No abstract available.
2.
Mikiashvili L, Kempker R, Chakhaia T, Bablishvili N, Avaliani Z, Lomtadze N, et al.
Clin Infect Dis
. 2023 Nov;
78(4):1043-1052.
PMID: 37962987
Background: There are scarce data on the clinical outcomes of persons retreated with new/companion anti-tuberculosis (TB) drugs for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). We sought to evaluate the efficacy and...
3.
Adamashvili N, Baliashvili D, Kuchukhidze G, Salindri A, Kempker R, Blumberg H, et al.
Int J Tuberc Lung Dis
. 2022 Mar;
26(4):326-333.
PMID: 35351237
Loss to follow-up (LTFU) is common among patients with drug-resistant TB (DR-TB) receiving second-line TB treatment; however, little is known about outcomes after LTFU, including mortality. To determine rates of...
4.
Smith A, Gujabidze M, Avaliani T, Blumberg H, Collins J, Sabanadze S, et al.
Int J Tuberc Lung Dis
. 2021 Jul;
25(8):632-639.
PMID: 34330348
National Center for Tuberculosis and Lung Diseases (NCTLD), Tbilisi, Georgia. To determine clinical outcomes of patients with tuberculous meningitis (TBM) treated with an intensified regimen including a fluoroquinolone (FQ) and...
5.
Graciaa D, Kempker R, Sanikidze E, Tukvadze S, Mikiashvili L, Aspindzelashvili R, et al.
Int J Tuberc Lung Dis
. 2021 Mar;
25(3):167-170.
PMID: 33688804
No abstract available.
6.
Mikiashvili L, Kipiani M, Schechter M, Avaliani Z, Kiria N, Kempker R
Int J Tuberc Lung Dis
. 2020 Apr;
24(4):436-443.
PMID: 32317069
Data on the long-term use of linezolid (LZD) in the treatment of drug-resistant pulmonary tuberculosis (DR-PTB) are limited. To assess safety, tolerability and efficacy of LZD-containing regimens for the treatment...
7.
Schechter M, Fayfman M, Khan L, Carr K, Patterson S, Ziemer D, et al.
J Diabetes Complications
. 2020 Jan;
34(4):107516.
PMID: 31924527
Aims: Diabetes-related amputations are typically preceded by a diabetic foot ulcer (DFU) but models to assess the quality of care are lacking. We investigated a model to measure inpatient and...
8.
Kempker R, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, et al.
Clin Infect Dis
. 2019 Nov;
71(9):2336-2344.
PMID: 31712809
Background: Bedaquiline and delamanid are newly available drugs for treating multidrug-resistant tuberculosis (MDR-TB); however, there are limited data guiding their use and no comparison studies. Methods: We conducted a prospective,...
9.
Buziashvili M, Mirtskhulava V, Kipiani M, Blumberg H, Baliashvili D, Magee M, et al.
Int J Tuberc Lung Dis
. 2019 Oct;
23(9):1005-1011.
PMID: 31615608
Treatment of multidrug-resistant tuberculosis (MDR-TB) is lengthy and utilizes second-line anti-TB drugs associated with frequent adverse drug reactions (ADRs). To evaluate the prevalence of and risk factors for ADRs among...
10.
Graciaa D, Machaidze M, Kipiani M, Buziashvili M, Barbakadze K, Avaliani Z, et al.
Int J Tuberc Lung Dis
. 2018 Oct;
22(11):1286-1292.
PMID: 30355407
Setting: A well-trained and sufficient tuberculosis (TB) workforce is essential for disease control, especially in an era of newly implemented diagnostics and medications. However, there are few reports on the...